Home
    • Plans Blog Contact
    Abbott Laboratories logo

    Abbott Laboratories

    ABT
    Last price US$103.06
    Market cap US$163.6b
    12M price change -18.03%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    DexCom IncDXCM Industry peer Edwards Lifesciences CorpEW Industry peer Iradimed CoIRMD Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Abbott Laboratories Overview

    Industry: Medical Devices

    Sector: Healthcare

    Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Mnire's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Abbott Laboratories into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jul 16, 2026

    Quarterly result summary

    Net sales was $12.6B (+13% YoY); EPS was $0.53 (reported).

    Net sales $12.6B +13% YoY
    Operating earnings $1.7B -17% YoY
    EPS $0.53 reported
    Net income $928M -48% YoY

    What changed

    • Net sales +13% YoY to $12.6B; EPS reported to $0.53.
    • Operating earnings -17% YoY to $1.7B.
    • Net income -48% YoY to $928M.

    Guidance / outlook

    We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Apr 29, 2026 Earnings release Earnings release Apr 16, 2026 SEC filing 10-K Feb 20, 2026 Earnings release Earnings release Jan 22, 2026 SEC filing 10-Q Oct 29, 2025 Earnings release Earnings release Oct 15, 2025 SEC filing 10-Q Jul 30, 2025 Earnings release Earnings release Jul 17, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Abbott Laboratories boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Devices industry , DexCom Inc , Edwards Lifesciences Corp , Iradimed Co are companies with high ratings.

    Return on Equity

    Score 4.49/5
    Abbott Laboratories stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Abbott Labor... ABT US$163.6b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 4.78/5
    Abbott Laboratories commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Abbott Labor... ABT US$163.6b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Devices industry , DexCom Inc , Edwards Lifesciences Corp , Iradimed Co are companies with high ratings.

    Leverage

    Score 2.29/5
    Abbott Laboratories registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Abbott Labor... ABT US$163.6b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Abbott Laboratories logo

    Abbott Laboratories

    US$103.06

    US$65.05

    -36.9% vs price

    US$163.6b

    2.36%

    -18.03%